"A+H"热度持续攀升。 市场有风险，投资需谨慎。本文不构成个人投资建议，也未考虑到个别用户特殊的投资目标、财务状况或需要。用户应考虑本文中的任何 意见、观点或结论是否符合其特定状况。据此投资，责任自负。 一方面，去年以来随着"A+H"热度持续攀升，市场便曾有关于A股医疗器械"双雄"迈瑞医疗、联影医疗 （688271.SH）是否会赴港上市的猜测——彼时，联影医疗对此回应称暂未有这一考虑。 另一方面，2025年上半年由于国内业务承压，迈瑞医疗的整体收入缩水近2成，但国际业务占比达到 50%，是未来业绩增长的重要看点。 如此来看，赴港上市确实有利于提升迈瑞医疗品牌的全球影响力。 接下来还会有哪些大市值的A股公司奔赴港股市场，正受到期待。 风险提示及免责条款 日前，有市场消息称迈瑞医疗（300760.SZ）已选定华泰证券、摩根大通负责处理香港IPO的准备工 作，稍后可能会引入更多投行参与。 经华尔街见闻·信风向接近迈瑞医疗人士确认，该消息属实，迈瑞医疗确实已在着手准备赴港上市。 这是继今年5月医药龙头恒瑞医药（600276.SH）登陆港股市场后，又一单A股千亿市值医疗公司瞄准港 交所——9月17日，迈瑞医疗的总市值 ...

Core Insights - The 2025 China International Service Trade Fair, themed "Digital Intelligence Leading the Way, Service Trade Renewed," focuses on health and wellness services, showcasing innovations in the medical and healthcare sectors [1][2] Group 1: Health and Wellness Innovations - The health service exhibition features advancements in artificial intelligence, digital healthcare applications, and medical service solutions, allowing attendees to experience the impact of technology on health management [3] - Notable innovations include a home medical-grade ECG monitoring device developed by a team from Fuwai Hospital and a groundbreaking electromagnetic-driven intramedullary nail created in collaboration with Tsinghua University [3][4] - The "Liver and Gallbladder Super Doctor Intelligent System" from Tsinghua Chang Gung Hospital provides specialized knowledge support for liver disease diagnosis and treatment, enhancing the capabilities of primary care physicians [4] Group 2: Integration of Traditional Chinese Medicine (TCM) and Technology - TCM institutions showcased the integration of traditional practices with modern technology, such as the "Guangyi·Qizhi Model 2.0" that enhances TCM diagnostic processes through AI [5] - Beijing Tongrentang presented a variety of health service experiences, including a smart medication service that offers tailored health solutions for different demographics [6][7] - The introduction of herbal toothpaste "Yin Yang Su" reflects TCM's adaptation to modern health needs, emphasizing natural ingredients for oral health [7] Group 3: Elderly Care Solutions - The aging population's needs are addressed through diverse and personalized elderly care solutions, such as the "Five-in-One" service system by Shoushan Fuhai, which integrates care, medical services, nutrition, housing, and support [8] - Xinyue Health introduced the "Home Elderly Care Kit" and "Ten Thousand Doctors" health service model, focusing on professional and precise home care solutions [8]

Group 1 - The private economy in Shanghai plays a crucial role, contributing nearly 30% of the city's industrial output and fixed asset investment, and accounting for three-quarters of new employment in 2024 [1] - Shanghai is home to 80% of the "specialized, refined, distinctive, and innovative" enterprises, as well as "little giant" companies, which are predominantly private enterprises [1] - The success of Black Lake Technology is attributed to breakthroughs in AI empowerment and equipment adaptability, enabling quality cultural and artistic resources to reach global markets without physical space limitations [3][4] Group 2 - Black Lake Technology has assisted over 30,000 factories in digital transformation, becoming the leading industrial software provider in the Asia-Pacific region [4] - The founder of Black Lake Technology noted that the digital transformation wave has led more enterprises to recognize the importance of digital solutions, which is a market opportunity for the company [4] - The establishment of Union Medical, which focuses on high-end medical equipment, has shifted the reliance on imported brands to domestic production, with products now in over 15,000 clinical and research institutions globally [6][8] Group 3 - Union Medical has formed deep collaborations with universities and hospitals, enhancing its innovation capabilities through industry-academia integration [8] - The company has cultivated nearly 1,000 quality domestic suppliers, including around 100 "specialized, refined, distinctive, and innovative" enterprises, contributing to the capital market [8] - The logistics technology company, Westwell Technology, has expanded its services from single logistics scenarios to multi-modal transport across 28 countries, emphasizing the importance of AI and application scenarios for product iteration [10]

Core Viewpoint - Mindray Medical is accelerating its secondary listing in Hong Kong, aiming to raise at least $1 billion, which would be one of the largest medical device secondary listings in Hong Kong this year [3][4]. Group 1: Business Structure and Financial Performance - Mindray Medical's business is divided into three main pillars: Life Information and Support, In Vitro Diagnostics, and Medical Imaging, which together form a robust revenue base [4]. - In 2024, the company expects total revenue of 36.73 billion RMB, with a net profit of approximately 11.7 billion RMB and R&D investment exceeding 4 billion RMB, maintaining a high ratio of about 11% of revenue [4]. - The company's international business revenue reached 16.4 billion RMB in 2024, a year-on-year increase of 21.3%, accounting for nearly 45% of total revenue [16]. Group 2: Technological Advancements - Mindray launched the "Qiyuan" critical care AI model in 2024, achieving over 95% accuracy in clinical applications, marking a significant step for domestic medical AI products [13]. - The company has integrated automation in laboratory systems to enhance efficiency and standardization, showcasing its capability in system integration [7][10]. Group 3: Globalization Strategy - Mindray's international strategy has evolved from exporting to localizing operations, with significant investments in local production and service teams in key markets like India and Brazil [16][14]. - The company has established localized production projects in 13 countries, transitioning from an "exporter" to a "multinational medical solution provider" [16]. Group 4: New Growth Areas - Mindray is actively expanding into minimally invasive surgery and high-value consumables, acquiring a 24.61% stake in Huatai Medical for 6.65 billion RMB to enter the cardiovascular intervention market [17]. - The minimally invasive surgery segment has seen over 90% growth, with significant breakthroughs in ultrasound knives and energy platforms [18]. Group 5: Market Challenges - The medical device industry faces challenges from centralized procurement policies, which have significantly reduced prices, impacting profit margins [21]. - Domestic competitors are rapidly emerging, necessitating Mindray to leverage R&D and system integration to maintain a competitive edge [21]. Group 6: Rationale for Hong Kong Listing - The timing of the Hong Kong secondary listing is driven by the need for capital to support significant investments in new headquarters and AI medical centers [22]. - Listing in Hong Kong will enhance Mindray's international brand recognition and attract global institutional investors [22][23]. Group 7: Conclusion - The secondary listing in Hong Kong represents a pivotal moment in Mindray's global strategy, emphasizing its capabilities in digital ecosystems, AI applications, and international market localization [24].

Core Viewpoint - The report from China Merchants Securities International indicates a decline in the mainland medical device industry, with a projected revenue drop of 3.8% and a net profit decrease of 12.8% year-on-year for the first half of 2025, suggesting a potential recovery phase starting in late 2025 to 2026 [1] Industry Summary - The overall revenue of the mainland medical device industry is expected to decline by 3.8% year-on-year in the first half of 2025, with a net profit drop of 12.8% and a non-recurring net profit decrease of 14.5% [1] - In the second quarter, the revenue is projected to fall by 5.5% year-on-year, with a net profit decline of 20.3% and a non-recurring net profit drop of 25% [1] - Approximately 53% of the 129 medical device companies analyzed reported revenue growth year-on-year, with 16% experiencing growth rates exceeding 20% and 37% within the 0-20% growth range [1] Future Outlook - The industry is anticipated to reach a turning point with a rebound in revenue and profit levels following disruptions from the pandemic and domestic procurement policies [1] - A new development phase for the mainland medical device industry is expected from the second half of 2025 to 2026, driven by improved internal policy environments and external market expansion [1] - The report suggests focusing on two main themes: domestic substitution and international expansion, with short-term attention on undervalued stocks showing clear performance improvement and long-term investment in high-growth sectors driven by innovation [1] Recommended Companies - The report highlights several companies for potential investment: Mindray Medical (300760.SZ), United Imaging Healthcare (688271.SH), MicroPort Scientific Corporation-B (02252), Huaitai Medical (688617.SH), and BGI Genomics (688114.SH) [1]

Group 1 - A total of 395 foreign institutions have participated in A-share listed company research since the beginning of the second half of the year, with a cumulative research count of 1,782 times as of September 16 [1] - Point72 has conducted the most research, with 59 instances, while Goldman Sachs, Bank of America Securities, and Citigroup have each exceeded 40 research instances [1] Group 2 - Key sectors attracting foreign institutional attention include industrial machinery, electrical equipment, electronic instruments, and medical care equipment [3] - Companies such as Estun, Huaming Equipment, Opto, Tianfu Communication, Lens Technology, United Imaging, Mindray, and BeiGene have received research from over 50 foreign institutions [3] - Estun's recent investor relations activity indicates that foreign institutions like Merrill Lynch, Citigroup, Morgan Stanley, BNP Paribas, Deutsche Bank, and Point72 are focused on the demand situation in downstream industries, with Estun expecting continued growth in automotive, electronics, and lithium battery sectors [3] - United Imaging has reported that its AI-driven smart operation system has significantly improved efficiency and reduced costs, supporting its long-term development in the global medical imaging industry [3] - Many foreign institutions believe that the A-share market currently offers rich investment opportunities, particularly in the technology and pharmaceutical sectors [3] - Morgan Stanley recently highlighted areas to watch in the A-share market, including AI computing and applications, innovative drugs, new energy (benefiting from policy adjustments), semiconductors, new consumption, resource products, and high-end manufacturing [3]

Core Viewpoint - The company, Dasan Intelligent, has secured a contract for the Xiaomi Wuhan Phase II smart project, valued at 23.869 million yuan, amidst a challenging financial environment marked by a significant decline in revenue and net profit [2][3][5]. Group 1: Project and Contract Details - Dasan Intelligent signed a contract with Mi Space Wuhan Information Technology Co., Ltd. for the Xiaomi Wuhan Phase II smart project, with a contract amount of 23.869 million yuan and a duration of 222 calendar days [2][3]. - The Xiaomi Wuhan Technology Park project covers an area of 143,000 square meters, including nine office buildings and three apartment buildings, aimed at research, production, and manufacturing of Xiaomi smart hardware products [3][4]. Group 2: Financial Performance - In the first half of 2025, Dasan Intelligent reported a revenue of 990 million yuan, a year-on-year decrease of 26.80%, and a net loss of 88.7633 million yuan compared to a profit of 9.3091 million yuan in the same period last year [5][6]. - The decline in revenue was attributed to fluctuations in industry demand and slower project implementation, leading to a decrease in signed contracts [5][6]. Group 3: Cost Management and Financial Strategy - To mitigate the adverse effects of declining revenue, Dasan Intelligent reduced its total expenses, including sales, management, R&D, and financial costs, which totaled 314 million yuan, down 6.12% from 335 million yuan in the previous year [5][6]. - The company's asset-liability ratio improved slightly to 62.03%, a decrease of 0.74 percentage points from the previous year [5]. Group 4: Innovation and Future Strategy - Dasan Intelligent is focusing on integrating AI technology with its self-developed IoT management platform, with the latest version, AIoT V7, launched on March 17, 2025 [6]. - The company reported a significant increase in the signing amount for AI-related IoT platform products, rising from 7.9668 million yuan to 25.0439 million yuan, a growth of 214.35% year-on-year [6]. - The company aims to enhance its market share in smart space products and services in Wuhan through the Xiaomi project and continues to prioritize technological innovation and risk management [4][7].

Market Sentiment - The current market sentiment score is 83, indicating an "overheated" market condition [6][10][22] - Historical trends show that when sentiment is below or near 50, the market tends to find support, while above 90, it may face resistance [10] Hot Themes Tracking - **Robotics Theme**: Tesla's "Master Plan 4" emphasizes AI and robotics, with Elon Musk stating that 80% of Tesla's future value will come from the Optimus robot. Related stocks include Wolong Electric (600580) and Changsheng Bearing (300718) [6] - **Medical Devices Theme**: Shanghai's government aims to approve over 500 new Class III medical device registrations by 2027, focusing on high-end imaging and AI medical devices. Related stocks include United Imaging Healthcare (688271) and Tuo Jing Life (300642) [6] - **Liquid Cooling Theme**: Due to high power consumption from new AI platforms, NVIDIA is pushing for the development of new micro-channel cooling technologies, which are significantly more expensive than current solutions. Related stocks include Yinlun (002126) and Plitite (688333) [6] Capital Flow Analysis - The top net inflow stocks include Gongxiao Daji (117,683.04 million), Sanhua Intelligent Control (109,105.26 million), and Liou Shares (89,821.81 million) [11] - The top net outflow stocks include Xinyi Sheng (149,021.64 million), Xiandao Intelligent (111,639.12 million), and Zhongji Xuchuang (108,779.29 million) [13][23] Industry Insights - The machinery and equipment sector shows significant net inflows, indicating investor confidence [17] - The electronic and communication sectors are experiencing notable net outflows, suggesting a bearish sentiment [18]

Core Viewpoint - The company, Dasan Intelligent, has secured a contract for the Xiaomi Wuhan Phase II smart project, valued at 23.869 million yuan, while facing significant revenue decline and net losses in the first half of 2025 [2][3][5]. Group 1: Project and Business Development - Dasan Intelligent has signed a contract with Mi Space Wuhan Information Technology Co., Ltd. for the Xiaomi Wuhan Phase II smart project, with a contract amount of 23.869 million yuan and a duration of 222 calendar days [2][3]. - The Xiaomi Wuhan Technology Park project covers an area of 143,000 square meters, including 9 office buildings and 3 apartment buildings, aimed at creating a large R&D center focused on smart hardware products [3][4]. - The company aims to establish a benchmark for smart space services in Wuhan through the Xiaomi project, enhancing its market share in smart space products and technical services [4][6]. Group 2: Financial Performance - In the first half of 2025, Dasan Intelligent reported a revenue of 990 million yuan, a year-on-year decrease of 26.80%, and a net loss of 88.7633 million yuan compared to a profit of 9.3091 million yuan in the same period last year [5][6]. - The decline in revenue is attributed to fluctuations in industry demand and slower progress on signed projects, leading to a significant drop in net profit [5][6]. - The company has implemented cost control measures, resulting in a 6.12% reduction in total expenses, amounting to 314 million yuan compared to 335 million yuan in the previous year [5][6]. Group 3: Innovation and Future Strategy - Dasan Intelligent has increased its R&D efforts, integrating its self-developed AIoT platform with AI technology, leading to a 214.35% increase in signed amounts for AIoT platform products [6][7]. - The company reported a 24.77% increase in revenue from AI-related products, rising from 10.8677 million yuan to 13.5599 million yuan [6]. - Looking ahead, Dasan Intelligent plans to strengthen technological innovation related to AI applications, optimize its business structure, and enhance risk management to achieve high-quality growth [7].

Group 1 - Nearly 400 foreign institutions have conducted intensive research on A-share listed companies since the second half of the year, with a total of approximately 1,800 research instances, indicating a positive signal of sustained interest in Chinese assets [1][3] - The focus of foreign investment research is primarily on high-end manufacturing and technological innovation sectors, including industrial machinery, electrical equipment, electronic instruments, and healthcare [2][5] - Point72 Asset Management has conducted the most research instances among foreign institutions, with 59 times, followed by Goldman Sachs and other major firms, all exceeding 40 instances [4][5] Group 2 - Companies such as Estun, Huaming Equipment, Optics Valley, and Mindray Medical have attracted attention from over 50 foreign institutions, indicating strong interest in these firms [5] - Estun has expressed optimism about continued growth in downstream demand in sectors like automotive, electronics, and lithium batteries for the second half of the year [7] - United Imaging Healthcare has highlighted the value added by AI in its operations, enhancing efficiency and cost reduction, which supports its long-term leadership in the global medical imaging industry [8] Group 3 - Several foreign giants believe that the A-share market presents abundant investment opportunities, particularly in technology and pharmaceuticals [9] - Morgan Stanley has expressed a positive outlook for A-shares, focusing on AI computing and applications, innovative drugs, and sectors benefiting from policy support and market trends [11] - The market strategy leaders emphasize the importance of semiconductor technology and AI applications, viewing them as critical components of the digital era and the new technological revolution [10]